Hemophilia Treatment Center Locator

The CDC supports a network of specialized health-care centers to prevent and reduce complications experienced by persons with certain blood disorders including Hemophilia A, Hemophilia B, and von Willebrand disease.

The Hemophilia Foundation has created The Chapter Center with information regarding the Chapter nearest you.

HemophiliaMoms.com

^® CSL Behring 2007. The product information on this site is intended for US residents only

Important Safety Information for Helixate^®FS

Helixate^® FS, Antihemophilic Factor (Recombinant), is a recombinant factor VIII treatment indicated for the treatment of hemophilia A.

The most frequently reported adverse events were local injection-site reactions, dizziness, and rash.

Known intolerance or allergic reactions to constituents of the preparation is a contraindication to the use of Helixate^® FS. Known hypersensitivity to mouse or hamster protein may be a contraindication to the use of Helixate^® FS.

Please see the full prescribing information.